Levetiracetam Ameliorates L-DOPA-Induced Dyskinesia in Hemiparkinsonian Rats Inducing Critical Molecular Changes in the Striatum

Parkinson's Disease

Volumn 2015, Issue , 2015, Pages

  Du, Huan ^a,b   Nie, Shuke ^a   Chen, Guiqin ^a   Ma, Kai ^a   Xu, Yan ^a   Zhang, Zhentao ^c   Papa, Stella M ^d   Cao, Xuebing ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Sanmenxia Central Hospital   (China)

^c RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENSERAZIDE; ETIRACETAM; LEVODOPA METHYL ESTER; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OXIDOPAMINE; PHOSPHOPROTEIN DARPP 32;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CORPUS STRIATUM; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; ENZYME PHOSPHORYLATION; LEVODOPA-INDUCED DYSKINESIA; MALE; MORNING DOSAGE; NEUROPROTECTION; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SCORING SYSTEM;

EID: 84937129885     PISSN: None     EISSN: 20420080     Source Type: Journal    
DOI: 10.1155/2015/253878     Document Type: Article

References (34)

1. J. A. Obeso, C. W. Olanow, and J. G. Nutt, ?Levodopa motor complications in Parkinson?s disease, ? Trends in Neurosciences, vol. 23, no. 10, pp. S2-S7, 2000.
2. E. Bezard, J. M. Brotchie, and C. E. Gross, ?Pathophysiology of levodopa-induced dyskinesia: potential for new therapies, ? Nature Reviews Neuroscience, vol. 2, no. 8, pp. 577-588, 2001.
3. P. Jenner, ?Molecular mechanisms of L-DOPA-induced dyskinesia, ? Nature Reviews Neuroscience, vol. 9, no. 9, pp. 665-677, 2008.
4. P. Calabresi, M. di Filippo, V. Ghiglieri, and B. Picconi, ?Molecular mechanism underlying levodopa-induced dyskinesia, ? Movement Disorders, vol. 23, supplement 3, pp. S570-S579, 2008.
5. C. R. Gerfen, ?D1 dopamine receptor supersensitivity in the dopamine-depleted striatum animal model of Parkinson?s disease, ? The Neuroscientist, vol. 9, no. 6, pp. 455-462, 2003.
6. L. Liang, M. R. DeLong, andS. M. Papa, ?Inversionofdopamine responses in striatal medium spiny neurons and involuntary movements, ? The Journal of Neuroscience, vol. 28, no. 30, pp. 7537-7547, 2008.
7. C. R. Gerfen, S. Miyachi, R. Paletzki, and P. Brown, ?D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase, ? Journal of Neuroscience, vol. 22, no. 12, pp. 5042-5054, 2002.
8. J. E. Westin, L. Vercammen, E. M. Strome, C. Konradi, and M. A. Cenci, ?Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamineD1 receptors, ? Biological Psychiatry, vol. 62, no. 7, pp. 800-810, 2007.
9. M. A. Cenci, A. Tranberg, M. Andersson, and A. Hilbertson, ?Changes in the regional and compartmental distribution of FosB-and JunB-like immunoreactivity induced in the dopamine-denervated rat striatumby acute or chronic L-DOPA treatment, ? Neuroscience, vol. 94, no. 2, pp. 515-527, 1999.
10. J. P. Doucet, Y. Nakabeppu, P. J. Bedard et al. , ?Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum, ? European Journal of Neuroscience, vol. 8, pp. 365-381, 1996.
11. E. Santini, E. Valjent, A. Usiello et al. , ?Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia, ?TheJournal of Neuroscience, vol. 27, no. 26, pp. 6995-7005, 2007.
12. M. Lebel, L. Chagniel, G. Bureau, and M. Cyr, ?Striatal inhibition of PKA prevents levodopa-induced behavioural and molecular changes in the hemiparkinsonian rat, ? Neurobiology of Disease, vol. 38, no. 1, pp. 59-67, 2010.
13. X. Cao, T. Yasuda, S. Uthayathas et al. , ?Striatal overexpression of δFosB reproduces chronic levodopa-induced involuntary movements, ? The Journal of Neuroscience, vol. 30, no. 21, pp. 7335-7343, 2010.
14. E. Bezard, M. P. Hill, A. R. Crossman et al. , ?Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTPtreated macaque, ? European Journal of Pharmacology, vol. 485, no. 1-3, pp. 159-164, 2004.
15. M. P. Hill, J. M. Brotchie, A. R. Crossman et al. , ?Levetiracetam interferes with the L-dopa priming process in MPTP-lesioned drug-naive marmosets, ? Clinical Neuropharmacology, vol. 27, no. 4, pp. 171-177, 2004.
16. R. C. Boldry, S. M. Papa, A. M. Kask, andT. N. Chase, ?MK-801 reverses effects of chronic levodopa on D1 and D2 dopamine agonist-induced rotational behavior, ? Brain Research, vol. 692, no. 1-2, pp. 259-264, 1995.
17. Y. Xu, Z. Zhang, K. Qin, S. M. Papa, and X. Cao, ?Quantitative autoradiographic study on receptor regulation in the basal ganglia in ratmodel of levodopa-inducedmotor complications, ? Journal of Huazhong University of Science and Technology-Medical Science, vol. 29, no. 2, pp. 156-162, 2009.
18. M. Lundblad, B. Picconi, H. Lindgren, and M. A. Cenci, ?A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function, ? Neurobiology of Disease, vol. 16, no. 1, pp. 110-123, 2004.
19. F. Stocchi, M. Tagliati, and C. W. Olanow, ?Treatment of levodopa-inducedmotor complications, ?MovementDisorders, vol. 23, no. 3, pp. S599-S612, 2008.
20. T. N. Chase and J. D. Oh, ?Striatal mechanisms and pathogenesis of Parkinsonian signs and motor complications, ? Annals of Neurology, vol. 47, no. 4, pp. S122-S130, 2000.
21. S. M. Papa, Y. P. Auberson, and J. T. Greenamyre, ?Prolongation of levodopa responses by glycine antagonists in parkinsonian primates, ? Annals of Neurology, vol. 56, no. 5, pp. 723-727, 2004.
22. I. Aubert, C. Guigoni, K. Hakansson et al. , ?Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia, ? Annals of Neurology, vol. 57, no. 1, pp. 17-26, 2005.
23. E. Santini, V. Sgambato-Faure, Q. Li et al. , ?Distinct changes in cAMP and extracellular signal-regulated protein kinase signalling in L-DOPA-induced dyskinesia, ? PLoS ONE, vol. 5, no. 8, Article ID e12322, 2010.
24. A. Berthet and E. Bezard, ?Dopamine receptors and l-dopainduced dyskinesia, ? Parkinsonism and Related Disorders, vol. 15, no. 4, pp. S8-S12, 2009.
25. O. Berton, C. Guigoni, Q. Li et al. , ?Striatal overexpression of DeltaJunD resets L-DOPA-induced dyskinesia in a primate model of Parkinson disease, ? Biological Psychiatry, vol. 66, no. 6, pp. 554-561, 2009.
26. P. K. Tekumalla, F. Calon, Z. Rahman et al. , ?Elevated levels of δFosB and RGS9 in striatum in Parkinson?s disease, ? Biological Psychiatry, vol. 50, no. 10, pp. 813-816, 2001.
27. J. J. Cereghino, V. Biton, B. Abou-Khalil, F. Dreifuss, L. J. Gauer, and I. Leppik, ?Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial, ? Neurology, vol. 55, no. 2, pp. 236-242, 2000.
28. C. -H. Lee, C. -Y. Lee, T. -S. Tsai, and H. -H. Liou, ?PKA-mediated phosphorylation is a novel mechanism for levetiracetam, an antiepileptic drug, activating ROMK1 channels, ? Biochemical Pharmacology, vol. 76, no. 2, pp. 225-235, 2008.
29. S. M. Papa, ?The cannabinoid system in Parkinson?s disease: multiple targets to motor effects, ? Experimental Neurology, vol. 211, no. 2, pp. 334-338, 2008.
30. K. E. Lyons and R. Pahwa, ?Efficacy and tolerability of levetiracetam in Parkinson disease patients with levodopa-induced dyskinesia, ? Clinical Neuropharmacology, vol. 29, no. 3, pp. 148-153, 2006.
31. B. Tousi and T. Subramanian, ?The effect of levetiracetam on levodopa induced dyskinesia in patients with Parkinson?s disease, ? Parkinsonism and Related Disorders, vol. 11, no. 5, pp. 333-334, 2005.
32. T. A. Zesiewicz, K. L. Sullivan, J. L. Maldonado, W. O. Tatum, and R. A. Hauser, ?Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson?s disease, ? Movement Disorders, vol. 20, no. 9, pp. 1205-1209, 2005.
33. P. Stathis, S. Konitsiotis, G. Tagaris, and D. Peterson, ?Levetiracetamfor the management of levodopa-induced dyskinesias in Parkinson?s disease, ? Movement Disorders, vol. 26, no. 2, pp. 264-270, 2011.
34. M. A. Cenci and C. Konradi, ?Maladaptive striatal plasticity in l-DOPA-induced dyskinesia, ? Progress in Brain Research, vol. 183, pp. 209-233, 2010.